论文部分内容阅读
慢性乙肝和丙肝的治疗性疫苗正在研究中,作为长期抗病毒治疗或仅仅是部分有效治疗的替代者,它们应能激活患者的免疫系统以与病毒抗争并最终控制病毒。治疗性疫苗接种的范例是除了激活体液免疫应答外,还要强效诱导抗病毒关键抗原的T细胞应答。作者评估了由乙肝表面抗原(HBsAg)和核心抗原(HBcAg)以及皂苷为基础的ISCOMATRIXTM佐剂所组成的新疫苗配方在C57BL/6小鼠中刺激T和B细胞应答的能力和在同源HBV转基因(HBVtg)中破坏耐受性的能力。在C57BL/6小
Therapeutic vaccines for chronic hepatitis B and C are under investigation and should be able to activate the patient’s immune system as a long-term antiviral or only partially effective treatment to fight the virus and ultimately control the virus. A paradigm of therapeutic vaccination is that in addition to activating the humoral immune response, it is also potent to induce a T-cell response to antiviral key antigens. The authors evaluated the ability of new vaccine formulations consisting of hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) and saponin-based ISCOMATRIXTM adjuvants to stimulate T and B cell responses in C57BL / 6 mice and the ability to stimulate T and B cell responses in homologous HBV Transgenic (HBVtg) ability to undermine tolerance. Small in C57BL / 6